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Background: Novel targeted agents have been increasingly developed and tested in clinical trials over the past
5–10 years, many with unknown and unanticipated side effects. We describe here a case of a patient with a history
of metastatic follicular thyroid carcinoma that we believe developed vandetanib–associated photoallergic dermatitis
while enrolled on a phase 1 clinical trial.
Case presentation: A 51-year-old Caucasian female with poorly differentiated, metastatic follicular thyroid carcinoma
presented with a cutaneous eruption that developed over 3 to 4 days while treated on phase 1 clinical trial with
vandetanib-based therapy. Given the concern for photoallergic dermatitis, vandetanib was discontinued and
supportive care provided including topical and oral steroid administration. Her cutaneous eruption improved and
she was successfully re-challenged with vandetanib.
Conclusion: Tyrosine kinase inhibitors, such as typo-vandetinib, with various therapeutic targets have come to the
forefront of oncologic therapy in recent years. It is important to have a better understanding of the side effect
profile and management in order to anticipate adverse events and maintain patient safety in future clinical trials.
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Investigational cancer therapeuticsBackground
Novel targeted agents have been increasingly developed
and tested in clinical trials over the past 5–10 years. In
clinical trials, drug reactions cannot always be antici-
pated and novel side effects can be encountered. Vande-
tinib is a multikinase inhibitor. Herein, we describe a
patient with metastatic follicular thyroid carcinoma who
we believe developed vandetanib–associated photoaller-
gic dermatitis while enrolled on a phase 1 clinical trial.Case presentation
A 51-year-old female with poorly differentiated, meta-
static follicular thyroid carcinoma presented with a cuta-
neous eruption that developed over 3 to 4 days. One
month prior to the development of the rash, she had* Correspondence: spihapau@mdanderson.org
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unless otherwise stated.begun therapy on a clinical trial with a combination of
vandetanib at 300 mg by mouth daily and everolimus, a
mammalian target of rapamycin (mTOR) inhibitor, at
5 mg by mouth daily (NCT01582191). She had a five-
year history of thyroid cancer which had progressed des-
pite thyroidectomy, radioactive iodine ablation therapy,
chemotherapy, targeted therapy, radiation, and other
novel agents. During follow up, her major complaint was
new rash. The erythematous eczematous plaques started
on the chest and posterior neck, with vesiculation of the
posterior neck plaques one day after the rash was first
noted. The lesions subsequently spread diffusely in sun-
exposed areas over the chest, the upper portion of the
back of the neck, and the bilateral forearms, sparing the
shoulders, abdomen, pelvis, and legs. Borders were well-
demarcated adjacent to sun-protected areas (Figure 1).
She described the rash as pruritic with desquamation.
The patient denied pain or involvement of the mucous
membranes. She reported heavy sun exposure approxi-
mately 2 weeks prior to the visit, but did use SPF 50ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Dermatologic adverse events to vandetanib. A) Anterior chest. B) Upper portion of the back of the neck. C and D) Shoulders and
arms showing sparing non-sun exposed areas.
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ever, she had, since that episode of heavy sun exposure,
daily sun exposure without use of sunscreen. She did
not report any new medications or changes to her
current regimen. She held the study drugs for 1 day
prior to the visit but otherwise was 100% compliant over
the past month. Due to Grade 3 skin rash, the patient
stopped the vandetanib and everolimus after being seen
in clinic.
The patient was prescribed a 4 mg methylprednisolone
dose pack, hydroxyzine for itching, clobetasol shampoo,
triamcinolone 0.1% cream and an antibiotic to prevent
superinfection. Aggressive photoprotection was also
recommended.
Subsequent dermatology evaluation revealed post-
inflammatory erythema with few areas of eczematous
dermatitis remaining. Photoallergic dermatitis was sus-
pected. A 4 mm punch biopsy showed superficial perivas-
cular dermatitis with eosinophils and focal spongiosis.
Histologic features were consistent with a reaction to an
internal antigen, such as a medication leading to photo al-
lergic reaction (Figure 2). Based on the timing of the rash
2 weeks after the initial severe sun exposure, the photodis-
tribution of the rash, history of vesiculation and pruritus,
and the histologic features, the patient was diagnosed with
photoallergic dermatitis. Laboratory results included a
normal complete blood count and comprehensive meta-
bolic panel.
Dermatology placed the patient on an oral prednisone
taper. Vandetanib continued to be held. After an additionalweek, the patient noted decreased erythema and no fur-
ther blistering. There were no new areas of involvement,
but she continued to have rare eczematous plaques that
may have been post inflammatory erythema.
The patient was re-challenged with vandetanib two
weeks after resolution of the rash after completion of
the steroid taper and with institution of strict photopro-
tection. The rash did not return and the patient is tole-
rating the study drug well. She continues to follow-up
with the phase 1 clinic.
Conclusions
Tyrosine kinase inhibitors, with various therapeutic tar-
gets, have come to the forefront of oncologic therapy in
recent years. With block buster drugs such as imatinib
for chronic myelogenous leukemia and gastrointestinal
stromal tumor and vemurafenib for melanoma, drug
companies and academic centers have formed collabora-
tions to develop these types of agents in multiple tumor
types. Vandetanib, an oral tyrosine kinase inhibitor,
targets vascular endothelial growth factor receptor 2, the
epidermal growth factor receptor, and RET [1,2]. It is ap-
proved by the United States Food and Drug Administration
and European Medicines Agency for the treatment of
advanced medullary thyroid cancer. Most recently, trials
with vandetanib have also been conducted in hepatocellu-
lar carcinoma, and non-small cell lung cancer [3].
Tyrosine kinase inhibitors are known to have side ef-
fects including nontrivial dermatologic toxicity, usually
manifesting as acneiform eruption, xerosis, eczema and
Figure 2 Hematoxolin and eosin (H&E) A) skin punch with superficial and deep perivascular lymphocytic infiltrate and epidermal spongiosis, B)
epidermal spongiosis with exocytosis of lymphocytes (*) C) perivascular lymphocytes with eosinophils (arrow).
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keratoacanthoma, squamous cell carcinomas), with grade
1–2 rashes reportedly occurring in 11-82% of patients [4].
Photodistributed reactions rarely occur and can be divided
into phototoxic or photoallergic etiologies [5]. Phototoxic
reactions occur because of the damaging effects of light-
activated compounds on cell membranes and, in someTable 1 Photosensitivity reactions to vandetanib reported in
First author, year (Ref.) Trial design Vandetanib arm Cont
Katsuyuki Kiura, 2008 [9] Phase IIa 100-300 mg/day N/A
Heidi Kong, 2009 [11] N/A N/A N/A
Chih-Hsiang Chang, 2009 [10] Phase II 300 mg/day N/A
Damien Giacchero, 2012 [12] Phase II/III 300 mg/day Placeinstances, DNA [5,6]. Photoallergic reactions are cell-
mediated immune responses to a light-activated compound
[5]. Phototoxic reactions develop in most individuals if
they are exposed to sufficient amounts of light and drug,
and develop within days of ultraviolet (UV) exposure [5].
Photoallergic reactions usually take days to weeks to de-
velop as the immune response develops [5]. Phototoxicthe literature
rol arm Enrollment no. Sample size Underlying cancer
53 12 NSCLC
N/A 1 Recurrent brain tumor
N/A 1 HCC
bo 63 23 Metastatic thyroid cancer
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tions. In our case, an eruption appeared 2 weeks after the
intense sun exposure, the lesions were pruritic, and lim-
ited to sun exposed areas therefore based on clinical
presentation was more likely a photoallergic rather than
phototoxic rash.
In the literature, few cases of photosensitivity reaction
to vandetanib have been described in detail. However, it
is important to note that in clinical trials with vandeta-
nib, rash is commonly listed as a side effect although
without specific detail given [7-9]. In one trial, up to
grade 2 rash developed in 12 of 46 (26%) patients using
vandetanib for metastatic breast cancer [8]. In other
cases more severe reactions have been reported. For
example, Chang et al. reports a case of a 60-year-old
man with hepatocellular carcinoma treated on trial with
vandetanib who developed bullous lesions related to sun
exposure [10]. Kong et al. reports two cases of photo-
toxicity induced hyperpigmentation [11]. Giacherro re-
ports 21 of 63 (33%) patients developed erythematous
skin eruptions ranging from exaggerated sunburn after
moderate sun exposure to a severe photodistributed ery-
thematous eruption associated with desquamation and
pruritus [12]. These trials findings are summarized in
Table 1.
Photosensitizing chemicals usually have a low molecu-
lar weight (200 to 500 Da), are planar, tricyclic, or poly-
cyclic configurations and often contain heteroatoms that
enable resonance stabilization [6,10]. They absorb UV
light, a characteristic that is essential to be regarded as a
photosensitizer. Vandetanib is a low–molecular weight
molecule with a polycyclic structure [6,10]. Thus, it is
plausible that vandetanib might be able to induce photo-
sensitivity [6,10]. It also appears the degree of sun expo-
sure does correlate with the severity of the rash [13].
In this patient, it is also important to consider photo
accentuation of a typical drug eruption or other non-
specific common polymorphous skin reactions found in
many patients on experimental agents. In this case, how-
ever, the eruption was thought to be most consistent
with a photoallergic reaction as the patient’s lesions were
limited to photo-distributed areas (including sharp bor-
ders adjacent to sun-protected skin), the delayed onset
of the eruption after the sun exposure and drug expos-
ure, and the negative re-challenge when the patient was
exercising strict photoprotection. The histology further
supported a photoallergic versus phototoxic reaction as
did the delayed onset of the eruption.
There are no defined guidelines as to the safety of re-
challenge in patients who experience severe photo-
induced reaction with vandetanib. It is been reported
that these reactions usually resolve with the use of
sunscreen and avoidance of sun exposure. In our case,
holding the drug and giving both topical and oralsteroids resulted in clearance of the rash. Ultimately,
vandetanib was resumed with strict photoprotection and
the patient tolerated continuance of therapy without fur-
ther issues.
In conclusion, treatment with vandetanib and similar
agents, either alone or in combination, may result in
photodistributed rashes including photoallergic reactions.
We hope to expand on the knowledge of skin reactions
with the use of vandetanib to aid future researchers.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
Abbreviations
mTOR: Mammalian target of rapamycin; UV: Ultraviolet.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors read and approved the final manuscript. JG participated in the
study concept and design, analysis of the case, drafting of the manuscript
and critical revision of the manuscript and important intellectual content.
SP participated in the study concept and design, analysis of the case,
drafting of the manuscript and critical revision of the manuscript and
important intellectual content, and study supervision. AP participated in the
study concept and design, analysis of the case, critical revision of the
manuscript and important intellectual content, and provided technical
support. JC participated in the study concept and design, analysis of the
case, critical revision of the manuscript and important intellectual content,
and provided technical support. VS participated in the study concept and
design, analysis of the case, drafting of the manuscript and critical revision of
the manuscript and important intellectual content.
Acknowledgements
We are indebted to Margaret Brown and Cristel Bastida.
Author details
1Division of Cancer Medicine, Medical Oncology and Hematology Fellowship
Program, University of Texas MD Anderson Cancer Center, 1515 Holcombe
Boulevard, Houston, TX 77030, USA. 2Department of Dermatology, University
of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,
TX 77030, USA. 3Department of Pathology, University of Texas MD Anderson
Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
4Department of Investigational Cancer Therapeutics, University of Texas MD
Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston
TX 77030, USA.
Received: 7 October 2014 Accepted: 21 January 2015
References
1. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474
inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor
growth following oral administration. Cancer Res. 2002;62(16):4645–55.
2. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al.
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity,
efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284–90.
3. Heymach JV. ZD6474–clinical experience to date. Br J Cancer.
2005;92 Suppl 1:S14–20.
4. Huang X, Patel S, Ahmed N, Seiter K, Liu D. Severe toxicity of skin rash, fever
and diarrhea associated with imatinib: case report and review of skin
toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther.
2009;2:215–9.
Goldstein et al. BMC Dermatology  (2015) 15:2 Page 5 of 55. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic
reactions. Expert Opin Drug Saf. 2007;6(4):431–43.
6. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism,
prevention and management. Drug Saf. 2002;25(5):345–72.
7. Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer
patients treated with vandetanib: systematic review and meta-analysis. J Clin
Endocrinol Metab. 2012;97(4):1125–33.
8. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, et al. A
multicenter phase II trial of ZD6474, a vascular endothelial growth factor
receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor,
in patients with previously treated metastatic breast cancer. Clin Cancer Res.
2005;11(9):3369–76.
9. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, et al. A
randomized, double-blind, phase IIa dose-finding study of Vandetanib
(ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac
Oncol. 2008;3(4):386–93.
10. Chang CH, Chang JW, Hui CY, Yang CH. Severe photosensitivity reaction to
vandetanib. J Clin Oncol. 2009;27(27):e114–5.
11. Kong HH, Fine HA, Stern JB, Turner ML. Cutaneous pigmentation after
photosensitivity induced by vandetanib therapy. Arch Dermatol.
2009;145(8):923–5.
12. Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L,
et al. A new spectrum of skin toxic effects associated with the multikinase
inhibitor vandetanib. Arch Dermatol. 2012;148(12):1418–20.
13. Fava P, Quaglino P, Fierro MT, Novelli M, Bernengo MG. Therapeutic hotline.
A rare vandetanib-induced photo-allergic drug eruption. Dermatol Ther.
2010;23(5):553–5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
